Pair page
Mazdutide with Tirzepatide
Mechanism-tag overlap and published literature for Mazdutide and Tirzepatide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
dual-glp-1-glucagon-receptor-agonistincretin-peptide
dual-gip-glp-1-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Mazdutide and Tirzepatide have published these mechanism-level observations. Not a co-administration recommendation.
These are alternative incretin-class options, not concurrent stack partners. Patients do not combine two incretin agonists — this creates additive GI toxicity without additive benefit. Choice among mazdutide, tirzepatide, and semaglutide depends on availability, patient phenotype, and insurance / regulatory access. Mazdutide may have specific advantages in MAFLD phenotype given glucagon-mediated hepatic lipid reduction.
Quick facts
Mazdutide
Tirzepatide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Mazdutide | Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736. DOI: 10.1056/NEJMoa2411528. (Pivotal GLORY-1 Phase 3 publication, May 2025.) PMID 40421736 | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, Qian L, et al; DREAMS-1 Investigators. Mazdutide in Chinese adults with untreated type 2 diabetes: DREAMS-1 Phase 3 trial. Nature. 2025. (Accelerated Article Preview publication, late 2025; part of back-to-back Nature release.) | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, et al; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral medication: DREAMS-2 Phase 3 trial. Nature. 2025. (Back-to-back with DREAMS-1.) | human trial, Phase 3 |
| 2025 | Mazdutide | Innovent Biologics press release. Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature. November 2025. | human trial, Phase 3 |
| 2025 | Mazdutide | BioSpace press release. Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3). May 15, 2025. | human trial, Phase 3 |
| 2018 | Mazdutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10… PMID 29945726 | human trial, Phase 2 |
| 2022 | Mazdutide | Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical… PMID 36337827 | human trial, Phase 1 |
| 2022 | Mazdutide | Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID: 35750890. (Phase 1b / dose… PMID 35750890 | human trial, Phase 1 |
| 2025 | Mazdutide | Innovent Biologics press release. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 19, 2025. | human study |
| 2017 | Mazdutide | Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. PMID: 28733905. (Class review.) PMID 28733905 | human study |
| 2009 | Mazdutide | Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266. PMID: 19602537. (Preclinical proof-of-concept for the dual-agonist class.) PMID 19602537 | preclinical, in vivo |
| 2018 | Mazdutide | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. (GLP-1 mechanism framework.) PMID 29617641 | research article |
| 2022 | Tirzepatide | Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11)… PMID 36152639 | human trial, Phase 3 |
| 2021 | Tirzepatide | Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al.; SURPASS-1 Investigators. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet.… PMID 34186022 | human trial, Phase 3 |
| 2021 | Tirzepatide | Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group,… PMID 34370970 | human trial, Phase 3 |
| 2021 | Tirzepatide | Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 202… PMID 34672967 | human trial, Phase 3 |
| 2025 | Tirzepatide | Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al.; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. PMID: 39536238. PMID 39536238 | human trial |
| 2024 | Tirzepatide | Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al.; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. PMID 38078870 | human trial |
| 2024 | Tirzepatide | Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al.; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID: 38912654. PMID 38912654 | human trial |
| 2023 | Tirzepatide | Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al.; SURMOUNT-2 Investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275. PMID 37385275 | human trial |
| 2022 | Tirzepatide | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PMID 35658024 | human trial |
| 2022 | Tirzepatide | Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PMID: 3513… PMID 35133415 | human trial |
| 2021 | Tirzepatide | Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PMID 34170647 | human trial |
| 2018 | Tirzepatide | Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID: 30473097. PMID 30473097 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Mazdutide and Tirzepatide been studied together?
Researchers have published mechanistic-level co-administration discussion of Mazdutide and Tirzepatide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Mazdutide and Tirzepatide share?
Mazdutide and Tirzepatide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Mazdutide and Tirzepatide?
Mazdutide: Not approved. Tirzepatide: Approved (T2D 2022, obesity 2023, OSA 2024). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Mazdutide and Tirzepatide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Mazdutide profile and the Tirzepatide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026